PROFILES - Connect with RTRN Researchers

Jorge Duconge
Title Professor
Faculty Rank Professor
Degree PhD, MSc, BSc Pharm
Institution University of Puerto Rico
Department Pharmaceutical Sciences
Clusters Cardiovascular and Related Diseases
Address
UPR-Medical Sciences Campus
School of Pharmacy
PO Box 365067
Pharmacy Bldg., 3rd floor, Rm 325-14
City San Juan
State PR
Postal Code 00936-5067
Telephone (787) 758-2525 ext. 5312
Fax (787) 767-2796
Email
QR Barcode

Other Positions icon

Title Investigator (WOC)
Institution VA Caribbean Healthcare System
Department Pharmacy
Division Research
 
Title Collaborator
Institution Hartford Hospital
Division Genetics Research Center

Awards and Honors icon

1995 University of Havana, Cuba Summa Cum Laude
1999 National Council of Scientific Degrees, Cuba Best PhD Thesis in Pharmaceutical Sciences
2002 Cuban Public Health Services Annual National Prize of Health Sciences
2006 School of Pharmacy, UPR-MSC Teacher of the Year
2007 NIH Grant#5P20RR01112, Clinical Research Center infrastructure initiative Pilot Projects Award (RCRII)
2008 NICHD, NIH Grant#5G11HDO46326, EARDA Program
2008 UPR-MSC RCMI Program; NCRR, NIH RCMI Mentorship Award
2011 NHLBI, NIH Grant#HL110393, PGt of Warfarin in Puerto Rican Patients using a Physiogenomics Approach (SC2)
2013 American Society of Health-System Pharmacists (ASHP) 2013 ASHP Foundation Literature Award
2014 NHLBI, NIH Grant#HL123911, Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics (SC1)
2017 NIMHD, NIH Grant#U54MD007600/5318, Adopting a Precision Medicine Paradigm in Puerto Ricans on Clopidogrel, RCMI

Narrative icon

  Dr. Jorge Duconge is a Professor of Pharmacokinetics and Pharmacogenomics in the Department of Pharmaceutical Sciences at the School of Pharmacy, University of Puerto Rico Medical Sciences Campus.
Dr. Duconge obtained a Baccalaureate in Pharmacy, BSc Pharm (1995, Gold Medal Honors List); Master’s degree in Experimental Pharmacology (1997); and a PhD degree (1999) from the School of Pharmacy, University of Havana. He also completed an advanced Residential Program in pharmacokinetics at Cambridge University, UK in 1998; population pharmacokinetics at State University of New York at Buffalo in 2006, and pharmacometrics (University of Auckland in New Zealand, 2003). He has also spent a mini-sabbatical at Hartford Hospital and the Genomas Laboratory of Personalized Health, CT in 2007, receiving hands-on training on DNA-typing. In addition, he completed the Genetic Analysis for Admixture and Epidemiology Studies in Latin American Populations (University of California at San Francisco (UCSF), USA) in 2010 and a hands-on workshop in next generation sequencing at the University of Pittsburgh/ Pittsburgh Supercomputing Center in 2013.
His research areas include pharmacogenomics, pharmacokinetics, pharmacometrics and kinetics of drug action. From 1999 to 2004, Dr. Duconge headed the Pharmacokinetic Lab, Center for Biological Evaluation and Research in Havana, performing over 34 research projects and receiving 4 research grants. Since 2005 to date, he has completed various pharmacogenetic studies to determine prevalence of multiple pharmacogenes in the Puerto Rican population and their clinical association to medical outcomes. He also developed a novel PGt-guided algorithm to predict optimal warfarin doses in Puerto Ricans and measures of admixture pattern in this minority population. Moreover, a pharmacokinetic study of intermittent intravenous vitamin C infusions at high doses in prostate cancer patients was conducted. Currently, he is working on the physiogenomic analysis of the Caribbean Hispanics in order to infer their population structure and admixture pattern by using physiogenomic and ancestry markers, and also conducting pharmacogenetic association studies and implementing a DNA-guided algorithm for optimal warfarin management and dosing in Caribbean Hispanics. He is the author of more than 50 scientific publications including reviews, book chapters and research articles in peer-reviewed journals.

Programs, Membership, and Biomedical Research icon

BIOMEDICAL RESEARCH BIOMEDICAL - BASIC
BIOMEDICAL RESEARCH BIOMEDICAL - CLINICAL
BIOMEDICAL - BASIC BIOMEDICAL SCIENCES
BIOMEDICAL - BASIC GENETICS, HUMAN AND ANIMAL
BIOMEDICAL - BASIC MOLECULAR BIOLOGY
BIOMEDICAL - BASIC PHARMACOLOGY, HUMAN AND ANIMAL
BIOMEDICAL - CLINICAL PHARMACY

Publications icon

  Check NIH Public Access Policy Compliance

Loading
Please wait
1. Hernandez-Suarez DF, Núñez-Medina H, Scott SA, Lopez-Candales A, Wiley JM, Garcia MJ, Melin K, Nieves-Borrero K, Rodriguez-Ruiz C, Marshall L, Duconge J. Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. Drug Metab Pers Ther. 2018 Mar 28; 33(1):49-55.
2. Encarnación-Medina J, Rodríguez-Cotto RI, Bloom-Oquendo J, Ortiz-Martínez MG, Duconge J, Jiménez-Vélez B. Selective ATP-Binding Cassette Subfamily C Gene Expression and Proinflammatory Mediators Released by BEAS-2B after PM2.5, Budesonide, and Cotreated Exposures. Mediators Inflamm. 2017; 2017:6827194.
3. Hernandez-Suarez DF, Scott SA, Tomey MI, Melin K, Lopez-Candales A, Buckley CE, Duconge J. Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics. Ther Adv Cardiovasc Dis. 2017 Sep; 11(9):235-241.
4. Claudio-Campos K, Labastida A, Ramos A, Gaedigk A, Renta-Torres J, Padilla D, Rivera-Miranda G, Scott SA, Ruaño G, Cadilla CL, Duconge-Soler J. Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study. Front Pharmacol. 2017; 8:347.
5. Jiménez-Ramírez FJ, Castro LM, Ortiz C, Concepción J, Renta JY, Morales-Borges RH, Miranda-Massari JR, Duconge J. Role of treatment-modifying MTHFR677C>T and 1298A>C polymorphisms in metformin-treated Puerto Rican patients with type-2 diabetes mellitus and peripheral neuropathy. Drug Metab Pers Ther. 2017 03 01; 32(1):23-32.
6. Duconge J, Hernandez-Suarez DF. Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting. Curr Clin Pharmacol. 2017; 12(1):11-17.
7. Hernandez-Suarez DF, Claudio-Campos K, Mirabal-Arroyo JE, Torres-Hernández BA, López-Candales A, Melin K, Duconge J. Potential of a Pharmacogenetic-Guided Algorithm to Predict Optimal Warfarin Dosing in a High-Risk Hispanic Patient: Role of a Novel NQO1*2 Polymorphism. J Investig Med High Impact Case Rep. 2016 Oct-Dec; 4(4):2324709616682049.
8. Céspedes-Garro C, Naranjo MG, Rodrigues-Soares F, LLerena A, Duconge J, Montané-Jaime LK, Roblejo H, Fariñas H, Campos ML, Ramírez R, Serrano V, Villagrán CI, Peñas-LLedó EM. Pharmacogenetic research activity in Central America and the Caribbean: a systematic review. Pharmacogenomics. 2016 Oct; 17(15):1707-1724.
9. Duconge J, Ruaño G. Admixture and ethno-specific alleles: missing links for global pharmacogenomics. Pharmacogenomics. 2016 09; 17(14):1479-82.
10. Duconge J, Ramos AS, Claudio-Campos K, Rivera-Miranda G, Bermúdez-Bosch L, Renta JY, Cadilla CL, Cruz I, Feliu JF, Vergara C, Ruaño G. A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PLoS One. 2016; 11(1):e0145480.
11. Miranda-Massari JR, Rodríguez-Gómez JR, González MJ, Cidre C, Duconge J, Marín H, Grace K, McLeod HL. Metabolic Correction in Patients Sample with Diabetes: Clinical Outcomes and Costs Reductions. Int J Diabetes Res. 2016; 5(5):92-101.
12. Claudio-Campos K, Orengo-Mercado C, Renta JY, Peguero M, García R, Hernández G, Corey S, Cadilla CL, Duconge J. Pharmacogenetics of healthy volunteers in Puerto Rico. Drug Metab Pers Ther. 2015 Dec; 30(4):239-49.
13. Duconge J, Ruaño G. Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation. Pharmacogenomics. 2015; 16(15):1685-8.
14. Duconge J, Cadilla CL, Seip RL, Ruaño G. Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials. P R Health Sci J. 2015 Sep; 34(3):175-7.
15. Claudio-Campos K, Duconge J, Cadilla CL, Ruaño G. Pharmacogenetics of drug-metabolizing enzymes in US Hispanics. Drug Metab Pers Ther. 2015 Jun; 30(2):87-105.
16. Miranda-Massari JR, Gonzalez MJ, Fernando AS, Cidre C, Paz IM, Charvel J, Martínez V, Duconge J, Aponte A, Ricart CM. Metabolic Correction as a tool to improve diabetes type 2 management. Bol Asoc Med P R. 2015 Apr-Jun; 107(2):54-9.
17. Miranda-Massari JR, González MJ, Rodriguez-Gomez JR, Duconge J, Allende-Vigo MZ, Jiménez Ramirez FJ, Cintrón K, Ricart C, Zaragoza-Urdaz R, Berdiel MJ, Vázquez A. [Metabolic correction: a biochemical option against diseases]. Bol Asoc Med P R. 2015 Apr-Jun; 107(2):60-6.
18. González MJ, Miranda-Massari JR, Duconge J, Allende-Vigo MZ, Jiménez-Ramírez FJ, Cintrón K, Rodríguez-Gómez JR, Rosario G, Ricart C, Santiago-Cornier JA, Zaragoza-Urdaz R, Vázquez A, Hickey S, Jabbar-Berdiel M, Riordan N, Ichim T, Santiago O, Alvarado G, Vora P. Metabolic correction: a functional biochemical mechanism against disease--Part 1: concept and historical background. P R Health Sci J. 2015 Mar; 34(1):3-8.
19. Miranda-Massari JR, González MJ, Duconge J, Allende-Vigo MZ, Jiménez-Ramírez FJ, Hickey S, Vázquez A, Berdiel MJ, Cintrón K, Rodríguez-Gómez JR. Metabolic correction: a functional biochemical mechanism against disease--Part 2: mechanisms and benefits. P R Health Sci J. 2015 Mar; 34(1):9-13.
20. Humphries-Bickley T, Castillo-Pichardo L, Corujo-Carro F, Duconge J, Hernandez-O'Farrill E, Vlaar C, Rodriguez-Orengo JF, Cubano L, Dharmawardhane S. Pharmacokinetics of Rac inhibitor EHop-016 in mice by ultra-performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Feb 15; 981-982:19-26.
21. Valentín II, Rivera G, Nieves-Plaza M, Cruz I, Renta JY, Cadilla CL, Feliu JF, Seip RL, Ruaño G, Duconge J. Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. P R Health Sci J. 2014 Sep; 33(3):97-104.
22. Gonzalez MJ, Miranda-Massari JR, Berdiel MJ, Duconge J, Rodríguez-López JL, Hunninghake R, Cobas-Rosario VJ. High Dose Intraveneous Vitamin C and Chikungunya Fever: A Case Report. J Orthomol Med. 2014; 29(4):154-156.
23. Duconge J, Cadilla CL. CYP2D6's functional status associated with the length of hospitalization stay in psychiatric patients: a twist in the tale or evidence that matters? Biomark Med. 2013 Dec; 7(6):913-4.
24. Orengo-Mercado C, Nieves B, López L, Vallés-Ortiz N, Renta JY, Santiago-Borrero PJ, Cadilla CL, Duconge J. Frequencies of Functional Polymorphisms in Three Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican Population. J Pharmacogenomics Pharmacoproteomics. 2013 Mar 27; 4(113).
25. Ramos AS, Seip RL, Rivera-Miranda G, Felici-Giovanini ME, Garcia-Berdecia R, Alejandro-Cowan Y, Kocherla M, Cruz I, Feliu JF, Cadilla CL, Renta JY, Gorowski K, Vergara C, Ruaño G, Duconge J. Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients. Pharmacogenomics. 2012 Dec; 13(16):1937-50.
26. Gonzalez MJ, Miranda Massari JR, Duconge J, Riordan NH, Ichim T, Quintero-Del-Rio AI, Ortiz N. The bio-energetic theory of carcinogenesis. Med Hypotheses. 2012 Oct; 79(4):433-9.
27. Duconge J, Ruaño G. 'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine. Pharmacogenomics. 2012 Jul; 13(10):1097-100.
28. Valentin II, Vazquez J, Rivera-Miranda G, Seip RL, Velez M, Kocherla M, Bogaard K, Cruz-Gonzalez I, Cadilla CL, Renta JY, Feliu JF, Ramos AS, Alejandro-Cowan Y, Gorowski K, Ruaño G, Duconge J. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. Ann Pharmacother. 2012 Feb; 46(2):208-18.
29. Gonzalez MJ, Miranda Massari JR, Duconge J, Riordan NH, Ichim T. Schedule Dependence in Cancer Therapy: Intravenous Vitamin C and the Systemic Saturation Hypothesis. J Orthomol Med. 2012 Jan 01; 27(1):9-12.
30. Miranda-Massari JR, Gonzalez MJ, Jimenez FJ, Allende-Vigo MZ, Duconge J. Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control. Curr Clin Pharmacol. 2011 Nov; 6(4):260-73.
31. Rodríguez-Vélez R, Ortiz-Rivera OJ, Bower B, Gorowski K, Windemuth A, Villagra D, Kocherla M, Seip RL, D'Agostino D, Vergara C, Ruaño G, Duconge J. Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing. P R Health Sci J. 2010 Dec; 29(4):402-8.
32. González MJ, Miranda-Massari JR, Duconge J. Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later: comment on the article by Cabanillas. P R Health Sci J. 2010 Dec; 29(4):410-1; author reply 411-2.
33. Duconge J, Ruaño G. The Emerging Role of Admixture in the Pharmacogenetics of Puerto Rican Hispanics. J Pharmacogenomics Pharmacoproteomics. 2010 Oct 04; 1(101).
34. Villagra D, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Gorowski K, Bogaard K, Renta JY, Cruz IA, Mirabal S, Seip RL, Ruaño G. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies. Clin Chim Acta. 2010 Sep 06; 411(17-18):1306-11.
35. Seip RL, Duconge J, Ruaño G. Implementing genotype-guided antithrombotic therapy. Future Cardiol. 2010 May; 6(3):409-24.
36. González MJ, Rosario-Pérez G, Guzmán AM, Miranda-Massari JR, Duconge J, Lavergne J, Fernandez N, Ortiz N, Quintero A, Mikirova N, Riordan NH, Ricart CM. Mitochondria, Energy and Cancer: The Relationship with Ascorbic Acid. J Orthomol Med. 2010; 25(1):29-38.
37. Ruaño G, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Villagra D, Renta J, Holford T, Santiago-Borrero PJ. Physiogenomic analysis of the Puerto Rican population. Pharmacogenomics. 2009 Apr; 10(4):565-77.
38. Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, Renta JY, Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Ruaño G. Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics. Ethn Dis. 2009; 19(4):390-5.
39. Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, Renta JY, Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Ruaño G. For the patient. DNA makeup of Hispanic persons should be determined before warfarin prescription. Ethn Dis. 2009; 19(4):479-80.
40. Duconge J, Cadilla CL, Renta JY, Silén-Rivera P, Piovanetti P, García-Berdecía R, Castro-Rosario LM, Monzón S, Vélez L, Rosas G, Guerra JA, Santiago-Borrero PJ. Prevalence of CYP2C19 gene polymorphisms in the Puerto Rican population: a preliminary report. P R Health Sci J. 2008 Dec; 27(4):357-8.
41. Duconge J. Applying organ clearance concepts in a clinical setting. Am J Pharm Educ. 2008 Oct 15; 72(5):121.
42. LaSala A, Bower B, Windemuth A, White CM, Kocherla M, Seip R, Duconge J, Ruaño G. Integrating genomic based information into clinical warfarin (Coumadin) management: an illustrative case report. Conn Med. 2008 Aug; 72(7):399-403.
43. Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock W, Riordan NH. Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J. 2008 Mar; 27(1):7-19.
44. Ducongé J, Merino N, Alvarez D, Beausoleil I, Fernández-Sánchez E, Rodríguez L, Burt AD. Kinetics of monoclonal anti-epidermal growth factor receptor antibody (IOR EGF/r3)-induced apoptosis in human carcinoma bearing nude mice. P R Health Sci J. 2008 Mar; 27(1):35-41.
45. Duconge J, Miranda-Massari JR, González MJ, Taylor PR, Riordan HD, Riordan NH, Casciari JJ, Alliston K. Vitamin C pharmacokinetics after continuous infusion in a patient with prostate cancer. Ann Pharmacother. 2007 Jun; 41(6):1082-3.
46. García-Santana MA, Duconge J, Sarmiento ME, Lanio-Ruíz ME, Becquer MA, Izquierdo L, Acosta-Domínguez A. Biodistribution of liposome-entrapped human gamma-globulin. Biopharm Drug Dispos. 2006 Sep; 27(6):275-83.
47. Duconge J. The case of biotech-derived product equivalence: much ado about nothing? Curr Clin Pharmacol. 2006 May; 1(2):147-56.
48. Ducongé J, Rodríguez-Vera L, Valenzuela C, Alvarez D, Ramírez O, de la Luz-Hernández KR, Rabeza-Legón EY, Casacó A, Fernández-Sánchez E. Pharmacokinetic comparison of two recombinant human granulocyte colony-stimulating factor after subcutaneous administration in rabbits. Eur J Pharm Biopharm. 2005 Oct; 61(3):142-8.
49. Hernández-Bernal F, García-García I, González-Delgado CA, Valenzuela-Silva C, Soto-Hernández R, Ducongé J, Cervantes-Llano M, Blanco-Garcés E, Rodríguez V, García-Vega Y, Bello-Rivero I, Olivera-Ruano L, López-Saura P. Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers. Biopharm Drug Dispos. 2005 May; 26(4):151-9.
50. Duconge J, Prats PA, Valenzuela C, Aguilera A, Rojas I, Becquer MA, Alvarez D, Estrada L, Alfonso-Ortíz S, Hardy-Rando E, García-Pulpeiro O, Fernández-Sánchez E. Topical disposition of two strengths of a 125I-rhEGF jelly in rat skin wounds. Biopharm Drug Dispos. 2004 Jul; 25(5):193-201.
51. Ducongé J, Fernández-Sánchez E, Alvarez D. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable? Biopharm Drug Dispos. 2004 May; 25(4):177-86.
52. Duconge J, Castillo R, Crombet T, Alvarez D, Matheu J, Vecino G, Alonso K, Beausoleil I, Valenzuela C, Becquer MA, Fernández-Sánchez E. Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody. Eur J Pharm Sci. 2004 Feb; 21(2-3):261-70.
53. Garcia-Garcia I, Gonzalez-Delgado CA, Valenzuela-Silva C, Hernandez-Bernal F, Ferrero-Bibilonia J, Soto-Hernandez R, Cervantes-Llano M, Ducongé J, Correa-Fernandez A, Olivera-Ruano L, Lopez-Saura P. Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. Drugs R D. 2004; 5(5):271-80.
54. Duconge J, Fernández-Sánchez E, Macías A, Castillo R, Garcia I, Beausoleil I, Amador JF, Matheu J. Monoclonal anti-EGFreceptor antibody (ior-R3) pharmacokinetic study in tumor bearing nude mice: role of the receptor-mediated endocytosis on drug clearance. Eur J Drug Metab Pharmacokinet. 2002 Apr-Jun; 27(2):101-5.
55. Prats PA, Duconge J, Valenzuela C, Berlanga J, Edrosa CR, Fernández-Sánchez E. Disposition and receptor-site binding of (125)I-EGF after topical administration to skin wounds. Biopharm Drug Dispos. 2002 Mar; 23(2):67-76.
56. Fernandez-Sánchez E, Ducongé J, Castillo R, Garcia I, Beausoleil I, Macías A. Monoclonal anti-epidermal growth factor receptor (ior EGF/r3) antibody pharmacokinetic studies on nude mice I: a radio-receptor analysis applied to drug serum quantification. J Pharm Pharmacol. 2002 Jan; 54(1):59-64.
57. Morales AA, Ducongé J, Alvarez-Ruiz D, Becquer-Viart ML, Núñez-Gandolff G, Fernández E, Caballero-Torres I, Iznaga-Escobar N. Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studies. Nucl Med Biol. 2000 Feb; 27(2):199-206.
58. Morales AA, Núñez-Gandolff G, Pérez NP, Véliz BC, Caballero-Torres I, Ducongé J, Fernández E, Crespo FZ, Veloso A, Iznaga-Escobar N. Freeze-dried formulation for direct 99mTc-labeling ior-egf/r3 MAb: additives, biodistribution, and stability. Nucl Med Biol. 1999 Aug; 26(6):717-23.
59. Morales-Morales A, Ducongé J, Caballero-Torres I, Núñez-Gandolff G, Fernández E, Iznaga-Escobar N. Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma. Nucl Med Biol. 1999 Apr; 26(3):275-9.
60. Iznaga Escobar N, Morales AM, Ducongé J, Torres IC, Fernández E, Gómez JA. Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats. Nucl Med Biol. 1998 Jan; 25(1):17-23.

Abstracts icon

 

Loading
Please wait
1. Ramos AS, Alejandro-Cowan Y, Vazquez J, Valentin I, Rivera G, Renta J, Cruz I, Feliu JF, Cadilla CL, Seip R, Ruaño G, Duconge J. J Thrombosis and Thrombolysis. Pharmacogenetic-driven warfarin dosing algorithm in Puerto Rican patients. In: Warfarin Dosing Management/ Abstract J3. Special Issue: Proceedings of the 12th National Conference on Anticoagulant Therapy. 2013; 3(35):417.
2. Valentin II, Rivera G, Nieves M, Vazquez J, Cruz I, Renta J, Feliu JF, Cadilla CL, Duconge J. American Journal of Hematology. A Pharmacogenetic Safety Profile of Puerto Ricans on Warfarin Therapy. A10. THSNA meeting proceedings. 2012; 87(Suppl. 1):S152.

Original Articles icon

 

Loading
Please wait
1. Reynaldo G, Rodríguez L, Menéndez R, Solazabal J, Amaro D, Becquer MA, Colom Y, Gil H, Polo JC, Castañeda G, Jiménez-Vélez B, Duconge J, Fernández-Sánchez EM. . Journal of Pharmacy & Pharmacognosy Research. A comparative pharmacokinetic and pharmacodynamic study of two novel Cuban PEGylated rHuEPO versus MIRCERA® and ior®EPOCIM. 2018; 3(6):179-190.
2. Carlos Martes-Martinez; Cristian Méndez-Sepúlveda; Joel Millán-Molina; Matthew French-Kim; Heriberto Marín-Centeno; Giselle C. Rivera-Miranda; José J. Hernández-Muñoz; Jorge Duconge-Soler. Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico. P R Health Sci Journal. 2017; 3(36):165-172.

Proceedings of Meetings icon

 

Loading
Please wait
1. Bermudez-Bosch LA, Rivera G, Cruz I, Felici M, Ramos A, Duconge J. . American Journal of Hematology. A Proposal for an Individualized Pharmacogenetic-guided warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy. 2014; 89(1):E1.
2. Karla Claudio-Campos K, Orengo-Mercado C, Berrios L, Pagan R, Renta J, Cadilla C, Duconge J. . The FASEB Journal. CYP2C9*8 frequency distribution in Puerto Ricans: implications for warfarin dosing. 2014; 28(1):1141.10.
3. Ramos AS, Alejandro Y, Vazquez J, Valentin I, Rivera G, Cruz I, Cadilla CL, Renta J, Duconge J. . American Journal of Hematology. Pharmacogenetic-driven Warfarin Dosing Algorithm in Puerto Ricans. 2014; 89(1):E4.
4. Lojo L, Duconge J, Santiago-Borrero PJ. Pediatric Blood & Cancer. Integrating Combinatorial CYP2C9 and VKORC1 Genotypes into Clinical Warfarin Management in Puerto Rican Children with Thrombosis: An Illustrative Cases Study. 2010; 54(6):811-P162.

Reviews/Chapters/Editorials icon

 

Loading
Please wait
1. Duconge J. J Pharmacogenomics Pharmacoproteomics. Population Heterogeneity and Genomic Admixture: Relevance for Global Pharmacogenetics. 2014; 5(5):e141.
2. Duconge J, Escalera O, Korchela M, Ruaño G. Clinical Implications of Genetic Admixture in Hispanic Puerto Ricans: Impact on the Pharmacogenetics of CYP2C19 and PON1, D. Sanoudou (ed.). In: Clinical Applications of Pharmacogenetics, Chapter 7,. 2012; 151-164.
3. Seip RL, Duconge J, Ruaño G. Genotype-Guided Statin Therapy. In: Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory. A.H.B. Wu and K.T.J. Yeo (eds.). Molecular and Translational Medicine series. Chapter 10; Springer Science & Business Media (Humana Press), LLC, doi: 10.1007/978-1-60761-283-4. 2011; 155-174.

Research Resources icon

Funding Opportunities icon

Browse active NIH & NSF funding opportunities, requests for applications (RFAs), and program announcements (PAs)

Publications Timeline

Top MeSH Keywords

Tree Map of Keyword Semantic Groups (Categories)

Left-click a node to move down the tree, right-click the graph to move back up the tree

Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile:
 
Keyword
Last Name
Institution
 
Keywords
Warfarin
Anticoagulants
Aryl Hydrocarbon Hydroxylases
Hispanic Americans
Humans
See all (262) keywords
See all (11) people See all (60) people Search for (8) people
Feedback

RTRN Collaboration and Professional Networking Feedback